CureDuchenne unveils biobank to enhance research in Duchenne therapy
Date: 2019-10-14   Author: Paroma Bhattacharya  Category: #news

CureDuchenne unveils biobank to enhance research in Duchenne therapy

Duchenne muscular dystrophy (DMD) is a progressive disorder that involves loss of strength due to the alterations of dystrophin that helps keep muscle cells intact. It commonly affects young boys and has not witnessed a cure yet. However, various pharma and biotech companies are now on the verge of creating a permanent treatment for this condition.

CureDuchenne, a non-profit organization that is developing a treatment for Duchenne muscular dystrophy (Duchenne), has recently made some significant developments by announcing commencement of a biobank for Duchenne.

Reportedly, the biobank will help the company progress its research on Duchenne as well as develop a cure for the disease that is independent and accessible to researchers.

According to reliable sources, the company has joined hands with leading university-based biorepository, RUDER Infinite Biologics (RUCDR), for helping it with biobanking services as well as with Dr. Tahseen Mozaffar from UCI (University of California), Irvine, who will help with strategic implementation and development of the CureDuchenne Biobank.

Sources cite that the biobank intends to immediately commence collection of samples from the CureDuchenne Cares events across the country.

According to Debra Miller, Founder and CEO, CureDuchenne, their organization is dedicated to back projects that might treat Duchenne. She claims that it is essential to help researchers by offering an unrestricted and free access to the cell lines which are needed for Duchenne research.

Meanwhile, Dr. Andrew Brooks, Chief Operating Officer at RUDCR Infinite Biologics, said that their firm is thrilled to add Duchenne to the list of biobanks that could help cure genetic diseases like Duchenne.

Incidentally, CureDuchenne has also made some significant progress in adding high skilled members its team. Last month, the company appointed Lianna Orlando, PhD as the Senior Director of Research. The organization claims that she will benefit it by successfully evaluating and identifying strategic investments that would be focused on innovating the treatments for Duchenne muscular dystrophy.

Speaking on which, Debra commented that the company is delighted to welcome Lianna in their team, and is looking forward to working with her, as she finds and assesses the most capable Duchenne research that will transform the lives of patients.

Source Credit: https://www.cureduchenne.org/press-release/nonprofit-cureduchenne-launches-biobank-to-fuel-research-for-duchenne-muscular-dystrophy/



About Author


Paroma Bhattacharya

Paroma Bhattacharya

Paroma currently works as a content developer for AlgosOnline. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched content in diverse fields. Apart from...

Read More

More from Paroma


Post Recommendents

New York gives nod for the $26 billion T-Mobile and Sprint merger
Author: Saipriya Iyer

Manhattan’s federal judge has given a green signal to both the firms, allowing them to move forward with this merger.

After a yearlong battle against the T-...


Mota Ventures announced new JV with BevCanna Enterprises
Author: Pankaj Singh

Mota Ventures Corp., a renowned Vancouver based cannabis and CBD products company, has reportedly announced that it has entered into a definitive JV agreement with BevCanna Enterprises Inc., an emerging leader in infused cannabis beverages, to dis...


Flipkart, Amazon voice concerns over India’s proposed e-commerce tax
Author: Pankaj Singh

Flipkart, Amazon and other online retailers have demanded that India must roll back a proposed tax on all the third-party sellers on their respective platforms. The retailers stated that the burden of the agreement can...